do_not_disturb_altRecruitment Complete

Hypertension, Pulmonary

Bayer Identifier:

12916

ClinicalTrials.gov Identifier:

NCT00694850

EudraCT Number:

2007-003928-37

EU CT Number:

2023-507526-17-00
Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

Trial purpose

The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g. disturbed breathing) and outcome of pulmonary hypertension associated with lung fibrosis. Patients living with pulmonary hypertension associated with interstitial lung disease have a risk of increased number of hospitalisations because of worsening of their condition. Until now there is no approved medication for this disease. The current treatment of pulmonary hypertension associated with interstitial lung disease consists: of oxygen and medical treatment with vasodilators, e.g. so-called Calcium-antagonists. Therefore, there is a need for new drugs in the treatment of pulmonary hypertension associated with interstitial lung disease.

Key Participants Requirements

Sex

Both

Age

18 - N/A
  • - Diagnosis of an interstitial lung disease (usual interstitial pneumonia [UIP], nonspecific interstitial pneumonia [NSIP] or sarcoidosis) with high resolution CT and a total lung capacity (TLC) ≤ 90% or scleroderma associated pulmonary arterial hypertension (PAH) with total lung capacity (TLC) ≤ 80%.
    - Interstitial lung disease (ILD) must have been stable for at least 3 months (decrease in forced vital capacity (FVC)< 10% and diffusing capacity of lung for carbon monoxide (DLco) < 15 % in 3 months), i.e. no significant changes in pulmonary function testing and stable medication in terms of ILD (e.g., corticosteroids, immunosuppressants)
    - Mean pulmonary vascular resistance (PVR) > 400 dyne sec cm-5 or mean pulmonary arterial pressure (PAP mean) > 30 mmHg
    - Pulmonary capillary wedge pressure (PCWP) < 15 mmHg
    - Hemodynamic parameters at baseline (PAP, PCWP, cardiac output [CO], systemic mean arterial pressure [SAP])
    - High resolution computer tomography (HRCT) (should not be older than 12 months prior start of the study)
    - Heart rate > 55 beats per minute (BPM) and < 105 BPM at rest
    - Systolic blood pressure (SBP) > 90 mmHg
    -World Health Organisation (WHO) functional class II, III and IV
    - 6 Minute Walking Test (6MWT) > 100m and < 450 m
    - Stable controlled arterial hypertension according to current guidelines
    - Women of childbearing potential will be included in the study if the pregnancy test is negative and combination of condoms with a safe and highly effective contraception method (hormonal contraception with implants or combined oral contraceptives, certain intra-uterine devices [IUDs]) is granted.
  • - Co-medication:
     -- Patients pretreated with specific medication for pulmonary arterial hypertension (PAH) like endothelin receptor antagonists, prostaglandins or phosphodiesterase type 5 (PDE 5) blockers are excluded from the trial.
     -- Requirement for concomitant use of nitrates are contraindicated.
    - Pre-existing clinically relevant lung disease other than ILD including.
     -- Bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) with a forced expiratory volume in one second (FEV1)/FVC <60% pred., active tuberculosis
     -- Pulmonary hypertension of another WHO group (I, II, IV and V)
     -- Severe congenital abnormalities of the lungs, thorax and diaphragm
     -- Clinical or radiological evidence of a pulmovenoocclusive disease (PVOD)
    - Systemic hemodynamics
     -- Acute or severe chronic left heart failure (ejection fraction (EF) < 50%)
     -- Severe coronary artery disease (CAD; EF < 50%); CAD patients must be asymptomatic and stable
     -- Congenital or acquired valvular or myocardial disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension
    - Pulmonary function
     -- TLC predicted < 30%
     -- FEV1 (related to FVC) < 60% predicted
    - Blood gases at room air
     -- Arterial partial carbon dioxide pressure (Pa CO2) > 45 mmHg
     -- Arterial partial oxygen pressure (Pa O2) < 50 mmHg at O2 supply >/= 4 L/min
    - Peripheral organ function
     -- Moderate or severe hepatic insufficiency (Child-Pugh Class Band C and/or total bilirubin > 2.5 mg/dl (0.043 mmol/L); and/or hepatic transaminases >3 upper limit normal [ULN])
     -- Moderate or severe renal insufficiency (creatinine > 2 mg/dl) or creatinine clearance according to Cockroft-Gault formula < 35 mL/ min

Trial summary

Enrollment Goal
22
Trial Dates
August 2008 - October 2025
Phase
Phase 2
Could I Receive a placebo
No
Products
Adempas (Riociguat, BAY63-2521)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Active, not recruiting
München, 81377, Germany
Completed
Homburg, 66421, Germany
Completed
Dresden, 1307, Germany
Completed
Hannover, 30625, Germany
Completed
Gießen, 35392, Germany

Primary Outcome

  • Safety and tolerability
    date_rangeTime Frame:
    12 weeks treatment
    enhanced_encryption
    Safety Issue:
    yes

Secondary Outcome

  • Pharmacokinetics
    The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014
    date_rangeTime Frame:
    at every study visit except at run-in and Follow-up
    enhanced_encryption
    Safety Issue:
    no
  • 6-Minute Walk Test
    date_rangeTime Frame:
    at every study visit except at Follow-up
    enhanced_encryption
    Safety Issue:
    no
  • Modified borg scale
    The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014
    date_rangeTime Frame:
    at every study visit except at Follow-up
    enhanced_encryption
    Safety Issue:
    no
  • Quality of life assessments
    The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014
    date_rangeTime Frame:
    at baseline, after 6 weeks, after 12 weeks, Follow-up and at each visit during long term extension phase
    enhanced_encryption
    Safety Issue:
    No
  • Hemodynamic parameters
    date_rangeTime Frame:
    optional after 12weeks
    enhanced_encryption
    Safety Issue:
    No
  • Laboratory Parameters
    The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014
    date_rangeTime Frame:
    at each study visit during run-in and treatment phase and long term extension
    enhanced_encryption
    Safety Issue:
    yes
  • Electrocardiogram (ECG)
    The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014
    date_rangeTime Frame:
    at each study visit during run-in and treatment phase and long term extension
    enhanced_encryption
    Safety Issue:
    yes
  • Blood pressure and heart rate
    date_rangeTime Frame:
    at each study visit during run-in and treatment phase and long term extension
    enhanced_encryption
    Safety Issue:
    yes

Trial design

A multi-center, non-randomized, non blinded, non-controlled study to investigate the impact of multiple doses of BAY63-2521 on safety, tolerability, pharmacokinetics and pharmacodynamics in patients with interstitial lung disease associated pulmonary hypertension.
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
N/A
Blinding
Open Label
Assignment
Single Group Assignment
Trial Arms
1

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.